Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0499 Transporter Info | ||||
| Gene Name | SLCO1C1 | ||||
| Protein Name | Organic anion transporting polypeptide 1C1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs3794271 | ||||
| Site of GPD | chr12:20707159 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | G=0.4243/2125 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Infliximab | Drug Info | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Adalimumab | Drug Info | Rheumatoid Arthritis | Irrelevant to the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Etanercept | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 6 Drugs in Total | ||||
| Infliximab | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 2] | |
| Infliximab | Drug Info | Psoriasis | Correlated with the increased drug response in patients (compare with genotype AA) | [ 3] | |
| Etanercept | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 2] | |
| Etanercept | Drug Info | Psoriasis | Correlated with the increased drug response to tumor necrosis factor alpha (tnF-alpha) inhibitors in patients (compare with genotype AA) | [ 3] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 2] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Psoriasis | Correlated with the increased drug response in patients (compare with genotype AA) | [ 3] | |
| References | |||||
| 1 | GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013 May;14(7):727-34. | ||||
| 2 | PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014 Nov;15(14):1763-1769. | ||||
| 3 | Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J. 2015 Aug;15(4):322-5. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.